A study from Sengupta et al. conducted in the CSF collected from patients with mild AD, severe AD, and control individuals suggested that oTau could be used as an early biomarker in the CSF of AD individuals [145] in addition to already existing AD biomarkers, including Aβ42, phospho-Tau, and total Tau [146]. This evidence concerns the gene MAPT and Alzheimer disease.